The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,244 | -3,803 |
| Credit loss expense | 3,849 | - |
| Stock option compensation expense | 844 | 1,107 |
| Common stock issued for services | 55 | 333 |
| Bad debt expense | 0 | 37 |
| Ppp loan forgiveness | 0 | 0 |
| Amortization of debt discount | 39 | 67 |
| Amortization of right-of-use operating lease assets | 51 | 55 |
| Amortization of right-of-use finance lease asset | 18 | 33 |
| Operating lease liabilities | -50 | -50 |
| Finance lease liability | 22 | 43 |
| (gain) loss on investment in south korean joint venture | 0 | 9 |
| Depreciation expense | 34 | 78 |
| Accounts receivable | -410 | 2,368 |
| Inventories | -35 | 114 |
| Prepaid expenses and other assets | 22 | -33 |
| Accounts payable and accrued expenses-Entities Excluding Partially Owned Subsidiary | -539 | 484 |
| Deposits | 78 | -68 |
| Accounts payable and accrued expenses-Partially Owned Subsidiary | -139 | 144 |
| Contract liabilities | 0 | 0 |
| Net cash used in operating activities | -2,759 | -3,948 |
| Equipment purchases | 33 | 0 |
| Proceeds from note receivable | 289 | 192 |
| Net cash provided by (used in) investing activities | 256 | 192 |
| Proceeds from sale of common stock, net of commissions | 749 | 793 |
| Proceeds from debt obligation | 50 | - |
| Proceeds from warrant exercise | 0 | 0 |
| Proceeds from option exercise | 0 | 0 |
| Proceeds from sale of common stock-Beti Common Stock | 0 | 0 |
| Repayment of debt obligations | 9 | 9 |
| Proceeds from beti unit offering-Biolargo Energy Technologies Inc BETI | 100 | - |
| Proceeds from clyra medical preferred series b-Clyra Medical Preferred Stock Series B | 2,145 | - |
| Proceeds from clyra medical debt obligations | 0 | 1,261 |
| Proceeds from note payable | - | 50 |
| Proceeds from warrant exercise-Clyra Medical Technologies | 585 | 1,309 |
| Proceeds from sale of common stock-Clyra Medical Common Stock | 0 | 295 |
| Net cash provided by financing activities | 3,570 | 3,699 |
| Net effect of foreign currency translation | 8 | -20 |
| Net change in cash | 1,075 | -77 |
| Cash and cash equivalents at beginning of period | 3,548 | - |
| Cash and cash equivalents at end of period | 4,546 | - |
BIOLARGO, INC. (BLGO)
BIOLARGO, INC. (BLGO)